ArticleJournal of the National Cancer Institute2013
Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?
Article in Journal of the National Cancer Institute, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis.Cancer medicine · 2022Trial
- Article
- Factors associated with ductal carcinoma in situ (DCIS) treatment patterns and patient-reported outcomes across a large integrated health network.Breast cancer research and treatment · 2023Article
- Is palpable DCIS more aggressive than screen-detected DCIS?Surgery open science · 2023Article
- Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device.Scientific reports · 2022Article
- Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
- Ductal carcinoma in situ (DCIS): The importance of patient-reported outcomes (PRO).Current breast cancer reports · 2020Article
- Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS).JNCI cancer spectrum · 2018Article
- Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- Tamoxifen Initiation After Ductal Carcinoma In Situ.The oncologist · 2016Article
- Final results from a multicenter prospective study ( JROSG 05-5) on postoperative radiotherapy for patients with ductal carcinoma in situ with an involved surgical margin or close margin widths of 1 mm or less.Journal of radiation research · 2015Article
- Treatment patterns for ductal carcinoma in situ from 2000-2010 across six integrated health plans.SpringerPlus · 2015Article
- Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ.Annals of surgical oncology · 2014Article
- International variation in management of screen-detected ductal carcinoma in situ of the breast.European journal of cancer (Oxford, England : 1990) · 2014Article
- Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.Virchows Archiv : an international journal of pathology · 2014Article
- A comparison of the risks of in-breast recurrence after a diagnosis of dcis or early invasive breast cancer.Current oncology (Toronto, Ont.) · 2014Article
- Ductal carcinoma in situ: a rose by any other name.Journal of the National Cancer Institute · 2013Article
- Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corresponding to the increased use of mammography, the incidence of ductal carcinoma in situ (DCIS) has risen dramatically in the past 30 years. Despite its growing incidence, the treatment of DCIS remains highly variable and controversial. Although DCIS itself does not metastasize and is never lethal, it may be a precursor of invasive breast cancer and is a marker of increased breast cancer risk. Confusing a precursor lesion with cancer, many clinicians apply an invasive breast cancer treatment paradigm to DCIS patients, offering adjuvant radiation therapy and tamoxifen after diagnosis. In this commentary, we outline the issues associated with DCIS management--is DCIS a cancer, a precursor of cancer, or a marker of invasive carcinoma risk? Specifically, we argue that consideration be given to removing the term "carcinoma" from DCIS, using cancer "occurrence" to mean the diagnosis of invasive cancer after DCIS instead of "recurrence," and make the argument that a prophylactic paradigm of treatment after excision may be more appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.